Syntara Limited (ASX: SNT) - Share Price

- Current share price for SNT : $0.022

Syntara Limited (SNT), an ASX-listed company, is a clinical stage drug development company targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop medicines for blood cancers and conditions linked to inflammation and fibrosis.

SNT General Information ⁺

ASX Code	SNT
Website	http://www.syntaratx.com.au
Industry/Sector	Pharmaceuticals
Market Cap ($M)	43
SNT Share Price	$0.022
Day High	$0.024
Day Low	$0.022
Last Close	$0.022
SNT Share Price Movement	- ( No change )

Prices as at 16:40, 30 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Syntara Limited (SNT) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Syntara Limited (SNT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Syntara Limited (SNT) price-sensitive announcements

SNT - Quarterly Activities/Appendix 4C Cash Flow Report

Syntara Limited's quarterly report for the period ended 30 June 2026 highlights significan

Syntara Limited (SNT)
27 Jul 2026 | 9:18 AM

SNT - Encouraging SNT-4728 Phase 2 iRBD results

Syntara Limited announced encouraging preliminary results from its Phase 2 study of SNT-47

Syntara Limited (SNT)
6 Jul 2026 | 9:43 AM

SNT - Trading Halt

Syntara Limited (ASX: SNT) has requested a trading halt on its securities starting 3 July

Syntara Limited (SNT)
3 Jul 2026 | 9:23 AM

SNT - Results of Share Purchase Plan

Syntara Limited, a clinical-stage drug development company, announced the successful compl

Syntara Limited (SNT)
10 Jun 2026 | 3:07 PM

Syntara Limited (SNT) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Syntara Limited (SNT) ORDINARY FULLY PAID	Health Care	$43	Investor Update Webinar Presentation	28 Jul 2026 11:01AM	$0.023	$0.022	fallen by 4.35%
Syntara Limited (SNT) ORDINARY FULLY PAID	Health Care	$43	Investor Update Webinar	27 Jul 2026 9:56AM	$0.022	$0.022	fallen by 0%
Syntara Limited (SNT) ORDINARY FULLY PAID	Health Care	$43	Investor Presentation	27 Jul 2026 9:26AM	$0.022	$0.022	fallen by 0%
Syntara Limited (SNT) ORDINARY FULLY PAID	Health Care	$43	Quarterly Activities/Appendix 4C Cash Flow Report	27 Jul 2026 9:18AM	$0.022	$0.022	fallen by 0%
Syntara Limited (SNT) ORDINARY FULLY PAID	Health Care	$43	AZALOX MDS study advances to final Phase 1b cohort	20 Jul 2026 10:01AM	$0.023	$0.022	fallen by 4.35%
Syntara Limited (SNT) ORDINARY FULLY PAID	Health Care	$43	SNT-4728 Webinar Presentation	6 Jul 2026 1:13PM	$0.024	$0.022	fallen by 8.33%

SNT Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$12.26	-$0.80	-42.00%	0.00%	0.0%
2024A	-$13.67	-$1.40	-17.30%	0.00%	0.0%
2023A	-$11.36	-$1.70	408.80%	0.00%	0.0%

SNT Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Clarity Pharmaceuticals Ltd (CU6)	$780M	0.3002	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,172M	-0.7857	0.0743	1.2000	73.6141	68.5200	31.1455	0.00%	0.00%	0.00%
Syntara Limited (SNT)	$43M	-0.4196	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%

SNT Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	2.22	0.00
Market	0.59	17.40	1.61	1.01
Sector	0.47	34.10	2.36	2.36

SNT Directors

Name	Position	Start Date
Mr Gary Phillips	Chief Executive Officer, Managing Director	12 Mar 2013
Dr Simon Green	Non-Executive Director	16 Dec 2022
Mr Waradana Malitha Hashan De Silva	Non-Executive Director	16 Jan 2023
Dr Kathleen Mary Metters	Non-Executive Director, Non-Executive Chairman	7 Jun 2017

Syntara Limited (SNT) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
20 Feb 2025	DE SILVA, Waradana	Issued	Indirect Shares	9,753,442	$0.060	$585,206.520
23 Sep 2024	DE SILVA, Waradana	Issued	Indirect Shares	53,571,429	$0.028	$1,500,000.010
6 Feb 2024	GREEN, Simon	Issued	Indirect Shares	909,091	$0.022	$20,000.002

See all changes in directors' interest & trades for Syntara Limited (SNT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

SNT Management

Name	Position
David McGarvey	Chief Financial Officer and Company Secretary
Jana Baskar	Chief Medical Officer
Tim Luscombe	Company Secretary
Wolfgang Jarolimek	Head of Drug Discovery
Kristen Morgan	Head of Medical and Regulatory Affairs

SNT Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Syntara Limited (SNT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
296,159,707 (18.23%)	D and A Income Limited
172,160,847 (10.59%)	Platinum Asset Management Limited

SNT Calendar of Events

Date	Event
25 February 2027	Report (Interim)
27 August 2026	Report (Annual)
27 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us